(Q40611979)

22 September 2017

title

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis (English)

1 reference

22 September 2017

1 reference

Haller J Smith

1

1 reference

22 September 2017

Christen L Walters Haygood

2

1 reference

22 September 2017

Rebecca C Arend

3

1 reference

22 September 2017

Charles A Leath

4

1 reference

22 September 2017

J Michael Straughn

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

21 August 2015

1 reference

22 September 2017

1 reference

22 September 2017

volume

139

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

59-62

1 reference

22 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Projections of the cost of cancer care in the United States: 2010-2020.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Incorporation of pazopanib in maintenance therapy of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.08.013

10.1016/J.YGYNO.2015.08.013

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference